(Q33788626)

29 July 2017

1 reference

title

Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

Zoulim F

1

1 reference

29 July 2017

publication date

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

44

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

1-30

1 reference

Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vitro infection of woodchuck hepatocytes with woodchuck hepatitis virus and ground squirrel hepatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepadnavirus evolution and molecular strategy of adaptation in a new host

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Clinical experience with famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Carboxypeptidase D (gp180), a Golgi-resident protein, functions in the attachment and entry of avian hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The role of envelope proteins in hepatitis B virus assembly

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Mapping a region of the large envelope protein required for hepatitis B virion maturation.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Biosynthesis of the reverse transcriptase of hepatitis B viruses involves de novo translational initiation not ribosomal frameshifting

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Combination therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Loss and acquisition of duck hepatitis B virus integrations in lineages of LMH-D2 chicken hepatoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Double-stranded linear duck hepatitis B virus (DHBV) stably integrates at a higher frequency than wild-type DHBV in LMH chicken hepatoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Transfection of a rat hepatoma cell line with a construct expressing human liver annexin V confers susceptibility to hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17;18 translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

DNA vaccines and viral hepatitis: are we going around in circles?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Isolation of a hepadnavirus from the woolly monkey, a New World primate

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Drug-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The problem of antiviral therapy for chronic hepadnavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Experimental systems for the study of hepadnavirus and hepatitis delta virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Comprehensive allelotyping of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Specific vaccine therapy in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vitro neutralization of hepatitis B virus by monoclonal antibodies against the viral surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The hepatitis B virus X protein: the quest for a role in viral replication and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Nucleotide sequence of an infectious molecularly cloned genome of ground squirrel hepatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Biochemical and genetic evidence for the hepatitis B virus replication strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

trans-activation by the hepatitis B virus X protein shows cell-type specificity.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Interaction of the UV-damaged DNA-binding protein with hepatitis B virus X protein is conserved among mammalian hepadnaviruses and restricted to transactivation-proficient X-insertion mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Three recently described animal virus models for human hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vivo selection of duck hepatitis B virus pre-S variants which escape from neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Expression of functional hepatitis B virus polymerase in yeast reveals it to be the sole viral protein required for correct initiation of reverse transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Class II HLA alleles and hepatitis B virus persistence in African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In vitro activity of hepatitis B virus polymerase: requirement for distinct metal ions and the viral epsilon stem-loop

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Novel mechanism for reverse transcription in hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Origin and evolution of retroelements based upon their reverse transcriptase sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900056-X

7 January 2021

10.1016/S0166-3542(99)00056-X

Identifiers

DOI

1 reference

29 July 2017

1 reference